Chiesi Farmaceutici

Cyclica Inc. is a biotechnology company based in Toronto, Canada, that focuses on improving the drug discovery process through an integrated cloud-based platform enhanced by artificial intelligence. The company's key technologies, Ligand Design and Ligand Express, facilitate the design of novel molecules and the screening of small-molecule drugs, respectively. Ligand Design generates compounds while filtering for desired molecular and pharmacokinetic properties, whereas Ligand Express assesses drug candidates against a range of structurally-characterized proteins to evaluate their poly-pharmacological profiles. Cyclica employs advanced technologies such as MatchMaker™, a deep learning proteome screening tool, and POEM™, a supervised learning system for predicting molecular properties, to prioritize compounds effectively. Founded by Jason Mitakidis and Naheed Kurji in 2013, Cyclica aims to address unmet medical needs by creating precision medicines through a decentralized approach to drug discovery. The company has also established a strategic partnership with AUM Biosciences to further its mission.

Atopix Therapeutics Limited is a clinical-stage biopharmaceutical company based in Oxford, United Kingdom, focused on drug discovery for anti-inflammatory medicines. Founded in 2012, the company develops innovative oral treatments, specifically CRTH2 antagonists, aimed at addressing asthma, chronic allergic conditions, and various atopic diseases, including atopic dermatitis and allergic rhinitis. The lead candidate from Atopix is undergoing a Phase 2 clinical trial for moderate to severe atopic dermatitis at multiple prominent dermatology centers across Europe. As of December 2016, Atopix operates as a subsidiary of Chiesi Farmaceutici S.p.A.

Chiesi USA is a specialty pharmaceutical company based in Cary, North Carolina, dedicated to the development, acquisition, and commercialization of products aimed at addressing respiratory, inflammatory, and critical care diseases. The company focuses on discovering and advancing therapies for asthma and related conditions, leveraging its expertise to identify therapeutic niches within the specialty markets. By promoting its products to healthcare professionals through targeted sales forces, Chiesi USA aims to enhance patient outcomes while also generating revenue through the marketing of approved generic products via its subsidiary, Aristos Pharmaceuticals. The company maintains a robust pipeline of development projects, reflecting its commitment to innovation in the pharmaceutical industry.

Zymenex is a Scandinavian biopharmaceutical company dedicated to the development and commercialization of innovative enzyme replacement therapies aimed at treating rare and life-threatening genetic disorders. The company focuses on creating human recombinant enzymes that target specific diseases, particularly Lysosomal Storage Diseases, which hinder the body’s ability to break down certain molecules within cells. These conditions often impact children and are associated with serious health challenges and reduced life expectancy, with currently no available treatments. By advancing enzyme replacement therapy, Zymenex aims to improve the quality of life for affected patients, addressing a critical need in the medical landscape for effective therapeutic options.

uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Chiesi USA is a specialty pharmaceutical company based in Cary, North Carolina, dedicated to the development, acquisition, and commercialization of products aimed at addressing respiratory, inflammatory, and critical care diseases. The company focuses on discovering and advancing therapies for asthma and related conditions, leveraging its expertise to identify therapeutic niches within the specialty markets. By promoting its products to healthcare professionals through targeted sales forces, Chiesi USA aims to enhance patient outcomes while also generating revenue through the marketing of approved generic products via its subsidiary, Aristos Pharmaceuticals. The company maintains a robust pipeline of development projects, reflecting its commitment to innovation in the pharmaceutical industry.